SCHEMBL21349162

SCHEMBL21349162

CCNOCCOCC(=O)NC(CCCCNC(=O)COCCOCCNC(C)=O)C(=O)NCCN

nearest known ligand 0.51

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ GLP1R P43220 8/20 0.51
▸ SIRT6 Q8N6T7 1/20 0.44
▸ SIRT1 Q96EB6 1/20 0.44
▸ TLR2 O60603 7/20 0.37
▸ CHRNA1 P02708 1/20 0.34
▸ CHRNG P07510 1/20 0.34
▸ CHRNB1 P11230 1/20 0.34
▸ CHRND Q07001 1/20 0.34
▸ NMT2 O60551 1/20 0.34
▸ NMT1 P30419 1/20 0.34
▸ CA1 P00915 1/20 0.34
▸ CA2 P00918 1/20 0.34
▸ CPA1 P15085 1/20 0.33
▸ CPA2 P48052 1/20 0.33
▸ CPA4 Q9UI42 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21166939 0.92 GLP1R (0.55) GLP1RSIRT6SIRT1TLR2NMT2
SCHEMBL24111252 0.87 GLP1R (0.51) GLP1RSIRT6SIRT1TLR2NMT2
SCHEMBL12981270 0.85 GLP1R (0.56) GLP1RSIRT6SIRT1TLR2CPA1
SCHEMBL21349161 0.83 GLP1R (0.47) GLP1RSIRT6SIRT1TLR2CHRNA1
SCHEMBL21166941 0.82 GLP1R (0.52) GLP1RSIRT6SIRT1TLR2CHRNA1
SCHEMBL13475034 0.80 GLP1R (0.56) GLP1RSIRT6SIRT1TLR2NMT2
SCHEMBL17772689 0.80 GLP1R (0.62) GLP1RSIRT6SIRT1TLR2CHRNA1
SCHEMBL3484885 0.79 GLP1R (0.54) GLP1RSIRT6SIRT1TLR2CHRNA1
SCHEMBL4517738 0.79 GLP1R (0.54) GLP1RSIRT6SIRT1TLR2CHRNA1
SCHEMBL16326833 0.78 GLP1R (0.53) GLP1RSIRT6SIRT1TLR2CHRNA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11173109-B2 Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog and a co-polyamino acid ADOCIA (FR) 2021-11-16 — — US disclosed
US-20190274954-A1 Copositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog and a co-polyamino acid ADOCIA (FR) 2019-09-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190274954-A1 Copositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog and a co-polyamino acid IAPP, GLP1R, INSR GLP1R 2/4885SIRT6 4084/4885SIRT1 3919/4885
US-11173109-B2 Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog and a co-polyamino acid IAPP, INSR, GLP1R GLP1R 3/4885SIRT6 3807/4885SIRT1 3632/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback